Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis
- 926 Downloads
Weekly adalimumab dosing is used to treat juvenile idiopathic arthritis (JIA), uveitis, and other pediatric rheumatic diseases, but the safety of such dosing has not previously been studied. A retrospective chart review was conducted to assess the safety of weekly adalimumab. Demographic and clinical data were collected. Basic descriptive analysis was performed to assess for adverse events from weekly adalimumab. Sixty-nine patients at the University of Minnesota or Gillette Children’s Hospital were identified as treated with weekly adalimumab. Sixty (87%) were eligible for the chart review. Weekly adalimumab was used most commonly to treat uveitis (28%, 17/60) and rheumatoid factor-negative polyarticular JIA (25%, 15/60). Mean age at the start of weekly dosing was 13.9 years. The majority of patients were concurrently treated with a non-steroidal anti-inflammatory drug and methotrexate. Fifty-three (90%) patients continued weekly dosing for greater than 3 months. The mean duration of weekly adalimumab was 2 years. Throughout the duration of weekly dosing, 24/60 (40%) patients had documented minor infections not requiring antimicrobials and 24/60 (40%) had documented infections requiring antimicrobial treatment. Only three patients (5%) had an infection requiring hospitalization. Two patients (3%) developed autoimmune disease. Laboratory abnormalities and injection site reactions were rare. Weekly adalimumab was used most commonly to treat uveitis and rheumatoid factor-negative polyarticular JIA, and mean duration of weekly dosing was 2 years. Serious adverse events were rare.
KeywordsAdalimumab Juvenile idiopathic arthritis Pediatric rheumatology Uveitis
The authors would like to thank Betty Bishop, Registered Nurse, for proposing this research idea.
Compliance with ethical standards
All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. This study was approved by the University of Minnesota Institutional Review Board (IRB Code Number: 1511M80622).
- 1.Humira Package Insert (2016). http://www.rxabbvie.com/pdf/humira.pdf
- 6.van de Putte LB, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508–516. https://doi.org/10.1136/ard.2003.013052 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Kimball AB, Kerdel F, Adams D et al (2012) Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157:846–855. https://doi.org/10.7326/0003-4819-157-12-201212180-00004 CrossRefPubMedGoogle Scholar
- 9.Leonardi C, Sobell JM, Crowley JJ et al (2012) Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol 167:658–667. https://doi.org/10.1111/j.1365-2133.2012.11041.x CrossRefPubMedGoogle Scholar
- 13.Ghiti Moghadam M, Vonkeman HE, ten Klooster PM et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810–1817. https://doi.org/10.1002/art.39626 CrossRefPubMedGoogle Scholar
- 14.A LOOK AT TARGETED IMMUNE MODULATORS. WWW.ICER-REVIEW.ORG 1. Accessed 9/26/2017
- 20.Observational study of pediatric rheumatic diseases: the CARRA Registry. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02418442?term=carra+registry&rank=2. Accessed 1 Feb 2017